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Malaysia as a tropical country is a rich source of biologically active phytochemicals, 
which could be useful as an alternative to the current unsafe regimens of cancer 
treatment. This includes the use of cisplatin (CIS), the current chemotherapeutic drug to 
treat cervical cancer, the second most lethal cancer affecting women in Malaysia. 
Therefore, anti-tumor activities of zerumbone (ZER) were investigated in both in vitro 
and in vivo cervical cancer models. This natural compound was isolated from the edible 
plant Zingiber zerumbet, locally known as Lempoyang, through column chromatography 
and hydrodistillation methods. The chemical structure of ZER was confirmed using 
NMR. The cytotoxic effects of ZER were tested in human cervical cancer cell lines 
(HeLa) using MTT assay and compared concurrently to cisplatin. Zerumbone’s 
induction of HeLa cancer cell deaths were quantified using AO/PI double staining and 
flow cytometry. Transmission and scanning electron microscopic analyses were done to 
evaluate ultra-morphological changes. The effect of ZER on caspase-3 and caspase-9 
was evaluated colorimetrically in HeLa cells. The in vivo model of cervical 
intraepithelial neoplasia (CIN) was induced in pregnant female Balb/c mice using 
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Diethylstilboestrol (DES). Cervical tissues were stained with hematoxylin and eosin 
(H&E) and viewed under light microscopy and the in vivo antiproliferative properties of 
ZER was confirmed by the immunohistochemical staining of proliferating cellular 
nuclear antigen (PCNA) as a proliferation marker and the PCNA labeling index was 
obtained. Apoptosis (Bcl-2 & Bax) and G2/M-cell cycle arrest (cdc25B, cyclinB1 and 
Chk2) associated proteins were investigated using immunohistochemistry. Moreover, 
RT-PCR was used to amplify mRNA of Bcl-2, Bax, c-myc and β-actin genes. The 
genetic material was obtained by laser capture microdissection microscopy (LCMM). 
No previous toxicological investigations have been carried out on this compound. 
Hence, acute, sub-acute and sub-chronic toxicity studies and ZER was evaluated for its 
behavioural, biochemical and histo-pathological effects. Findings of NMR coincide to 
the previously published data. However, ZER was able to exert an antiproliferative 
effect towards HeLa when isolated by both hydrodistillation and column 
chromatography, with an IC50 of 20.30±1.1 μM and 20.41±0.9 μM (p>0.05, student t-
test, n=3), respectively. AO/PI-stained HeLa cells showed that ZER induced apoptosis in 
a time-dependent manner with insignificant statistical (p>0.05) difference in necrosis 
between various doses of this compound. Moreover, flow cytometric evaluation of the 
effect of ZER on DNA content by cell cycle phase distribution revealed that the cell 
populations at G0 and G2/M phases were significantly different (p<0.05) as compared to 
the untreated population. Antitumour activities of ZER were further confirmed by 
transmission and scanning electron microscopy investigations, which showed distinctive 
morphological changes corresponding to metaphasal arrest and the typical apoptosis. 
The colorimetric assay of caspase-3 and caspase-9 revealed a statistical significant 
difference between treated and untreated cells. In vivo model results disclosed that ZER 
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(16 mg/kg) has the capability to regress significantly (p<0.05, χ2 statistics) the 
proliferation of cervical intraepithelial neoplasia (CIN) from CIN3 to CIN1 resembling 
the anti-tumor effects of CIS 10mg/kg. Moreover, this antiproliferative property was 
further confirmed by the regression of the PCNA, an in vivo proliferation marker, which 
showed also a dose-dependent (p<0.05) effect of ZER on the PCNA labeling index 
(PCNA positive nuclei). It has been found that ZER also modulated the ratio of Bcl-2 
and Bax, which further supported the intonated levels of LCMM extracted and RT-PCR 
amplified mRNA of such proteins as well as c-myc oncogene, which was detected only 
in the CIN cancer group. Cervical tissues from female Balb/c mice treated with 16mg/kg 
of ZER, showed decreased levels of CyclinB1 and cdc25B immunoreactivity and 
associated with upregulation of Chk2 immunoexpression. Acute and subacute 
administration of ZER did not cause abnormalities on body weight, liver morphology or 
serum AST concentration. Moreover, sub-chronic study showed ZER did not modify 
significantly (p>0.05) serum concentrations of AST, ALP, ALT and GGT. No 
histopathological changes were observed in the hepatic, renal, cardiac and 
gastrointestinal tissues. These histomorphological findings were supported by the 
insignificant differences (p>0.05) between the mean lesion scores of hepatic and renal 
tissues. Collectively, results presented in this study demonstrated that ZER causes 
metaphasal blockage in HeLa cells, leading to growth inhibition and apoptosis, which 
was later confirmed to be through mitochondrial pathways. As ZER exhibits similar 
pharmacological activity to CIS, it possesses the potential to be developed as an 
antiproliferative agent for cervical cancer but producing less side effects, as the 
compound was shown to have no toxicological signs compared to the clinical 
complications of CIS. 
 v
Abstrak tesis yang dikemukakan keapda Senat Universiti Putra Malaysia sebagai 
memenunhi keperluan untuk ijazah Doktor Falsafah 
 
KESAN ANTIKANSER ZERUMBONE YANG DIPENCILKAN DARIPADA 
LEMPOYANG (Zingiber zerumbet) KE ATAS SEL KANSER SERVIKS MANUSIA 
DAN INTRAEPITHELIAL NEOPLASIA SERVIKS MENCIT 
 
Oleh 
 
SIDDIG IBRAHIM ABDEL WAHAB 
Januari 2009 
Pengerusi: Dr. Ahmad Bustamam, PhD 
Fakulti: Institut Biosains 
 
 
 
Malaysia merupakan sebuah negara yang kaya dengan sumber fitokimia yang aktif 
secara biologi yang mungkin berguna sebagai alternatif kepada rawatan kanser yang 
tidak selamat padamasa ini. Ini termasuklah, sisplatin (CIS), dadah kemoterapi pada 
masa kini untuk merawat kanser serviks, pembunuh kanser nombor dua di Malaysia. 
Oleh itu, aktiviti anti-kanser zerumbone telah diselidik secara in vitro dan in vivo dalam 
model kanser serviks. Hasilan semulajadi dipencilkan dari tumbuhan Zingiber zerumbet, 
lebih dikenali dengan lempoyang, melalui kaedah kromatografi kolum dan penyulingan. 
Struktur kimia ZER disahkan melalui NMR. Kesan sitotoksik ZER diuji ke atas jujukan 
sel kanser serviks (HeLa) menggunakan kaedah MTT dan dibandingkan dengan 
sisplatin. Pengaruhan kematian sel HeLa oleh ZER dikira menggunakan pewarnaan 
AO/PI  dan flow cytometry. Analisis mikroskop elektron imbasan dan transmisi telah 
dijalankan untuk menilai perubahan morfologi yang kecil. Kesan ZER terhadap kaspase-
3 dan kaspase-9 diuji secara kalorimetrik pada sel HeLa. Model in vivo untuk cervical 
intra-epithelial neoplasia (CIN) diaruh pada tikus Balb/c menggunakan Dietilstilbesterol 
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(DES). Tisu serviks diwarnakan menggunakan hematoxylin dan eosin (H &E) dan 
dilihat menggunakan microskop cahaya dan ciri-ciri antiproliferasi oleh ZER disahkan 
menggunakan pewarnaan immunohistokimia PCNA sebagai penunjuk proliferasi dan 
indeks penlabelan PCNA diperolehi. Protein yang berkaitan dengan apoptosis (Bcl-2 & 
Bax) dan G2/M-kitaran sel (cdc25B, cyclinB1 dan Chk2) diselidik menggunakan 
immunihistokimia. Sebagai tambahan, RT-PCR digunakan untuk amplifikasikan mRNA 
dari gen Bcl-2, bax, c-myc dan β-aktin. Bahan-bahan genetik pula didapati daripada 
mikroskop micro-pembedahan penangkap laser. Tiada kajian toksisiti telah dijalankan 
untuk kompaun ini. Oleh itu, kajian toksisiti akut, sub-akut dan sub-kronik oleh ZER 
dijalankan untuk melihat kesan kelakuan, biokimia dan histo-patologi. Penemuan 
menggunakan NMR adalah sama dengan kajian sebelumnya. Walau bagaimanapun, 
ZER yang dipencilkan menggunakan kedua-dua penyulihan hidro dan kromatografi 
kolum mampu untuk menunjukkan anti-proliferasi terdapat sel HeLa, dengan nilai IC50 
masing-masing adalah 20.30 dan 20.41. Pewarnaa AO/PI terhadap sel HeLa 
menunjukkan ZER mengaruh apoptosis yang dipengaruhi oleh masa secara tidak 
signifikan (p<0.05), berbeza dengan nekrosis untuk kepekatan dos kompaun yang 
berbeza. Tambahan pula, kajian flow cytometri untuk menentukan kesan ZER terhadap 
kandungan DNA oleh distribusi kitaran sel menunjukkan yang populasi sel pada fasa G0 
dan G2/M berbeza secara signifikan berbanding dengan populasi tidak dirawat. Aktiviti 
anti-tumor oleh ZER disahkan menggunakan mikroskop electron imbasan dan transmisi 
yang menunjukkan perubahan morfologi yang ketara bersandarkan perencatan metafasa 
dan aopotosis. Kaedah kalorimetri kaspase 3 dan kaspase 9 menunjukkan perbezaan 
yang signifikan di antara sel rawatan dan sel tidak di rawat. Keputusan kajian model in 
vivo menunjukkan ZER ( 16 mg/kg) mampu untuk merencatkan secara signifikan 
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(p<0.05) proliferasi neoplasia intraepithelia serviks dari CIN3 dan CIN1 yang sama 
kesan anti-tumornya dengan CIS 10 mg/kg. Tambahan pula, ciri-ciri anti-proliferasi 
disahkan memalui pertumbuhan PCNA, penunjuk anti-proliferasi in vivo yang juga 
menunjukkan kesan ZER terhadap indeks penlabelan PCNA (nukleus positif dengan 
PCNA). Adalah didapati juga bahawa ZER mampu untuk mengubah nisbah Bcl-2 dan 
Bax yang seterusnya menyokong paras ekstraks LCCM dan mRNA amplifikasi RTPCR 
seperti protein-protein dan juga onkogen c-myc yang hanya boleh dikesan dalam 
kumpulan kanser CIN. Tisu serviks dari tikus betina Balb/c yang dirawat dengan 16 
mg/kg ZER menunjukkan penurunan paras immun reaktif CyclinB1 dan cdc25B yang 
berkaitan dengan peningkatan pengawal aturan immuno ekspresi Chk2. Pengambilan 
akut dan sub-akut ZER tidak menyebabkan ketidak normalan terhadap berat badan, 
morfologi hati dan enzim (AST). Tambahan, kajian sub-kronik menunjukkan ZER tidak 
mengubah secara signifikan (p>0.05) paras AST, ALP. ALT dan GGT. Penemuan histo 
morfologi ini disokong oleh tidak perbezaan secara signifikan di antara pemarkahan 
lesion purata untuk tisu hati dan nuah pinggang. Tiada perubahan histopatologi dilihat 
pada tisu hati, buah pinggang, jantung dan usus. Secara kesuluruhan, keputusan 
menunjukkan ZER mampu menyebabkan penyekatan metafasa pada sel HeLa, yang 
membawa kepada perencatan pertumbuhan dan apoptosis, yang kemudiannya disahkan 
melalui tapak jalan mitokondria. ZER yang menunjukkan ciri-ciri farmakologi yang 
sama dengan CIS, menunjukkan ia potensi untuk dibangunkan sebagai agen anti-
proliferatisi untuk kanser serviks tetapi menghasilkan kesan sampingan yang kurang, di 
mana kompaun tersebut tidak mempunyai tanda-tanda toksisiti benbanding dengan 
komplikasi CIS.           
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PCNA immunoreactivity was not observed in the nuclei (Black 
arrow) (200X).  
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4.6.2 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 4mg/kg of 
ZER, using PCNA mouse monoclonal antibody and ARK 
immunohsitochemical kit.  
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4.6.3 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 8mg/kg of 
ZER, using PCNA mouse monoclonal antibody and ARK 
immunohsitochemical kit.  
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4.6.4 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 16mg/kg of 
ZER, using PCNA mouse monoclonal antibody and ARK 
immunohsitochemical kit.  
 
141 
4.6.5 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 10mg/kg of 
cisplatin, using PCNA mouse monoclonal antibody and ARK 
immunohsitochemical kit.  
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4.6.6 Immunohistochemical staining of cervical cancer tissue, from 142 
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female Balb/c mice (DES induced; 58 days old, n=6), with 
ARK immunohsitochemical kit with the primary antibody 
(PCNA mouse monoclonal antibody.  
 
4.6.7 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6), with ARK 
immunohsitochemical with missing the primary antibody 
(PCNA mouse monoclonal antibody.  
 
143 
4.7 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 16mg/kg of 
ZER (Right) showing down-expression of Bcl-2.  
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4.8 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 16mg/kg of 
ZER (Left) showing an overexpression of Bax.  
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4.9 Immunohistochemical staining of normal cancer tissue, of 
female Balb/c mice (58 days old, n=6) showing (Left) low 
immunoreactivity of Bax and (Right) high immunoreactivity 
of Bcl2 (Black arrow) (200X). 
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4.10 Immunohistochemical staining of cervical cancer tissue, from 
female Balb/c mice (58 days old, n=6) treated with 10mg/kg of 
cisplatin (Right) showing an overexpression of Bax.  
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4.11 Cervical cancer tissue stained with Cyclin B1 antibody using 
ARK immunohsitochemical kit. 
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4.12 Cervical cancer tissue stained with cdc25B Ab using ARK 
immunohsitochemical kit. (Right photo) Balb/c mice (58 days 
old, n=6) cervical tissues from DES induced CIN, note nuclear 
staining of tumor cells.  
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4.13 Cervical cancer tissue stained with Chk2 antibody using ARK 
immunohsitochemical kit. Right: Balb/c mice (58 days old, 
n=6) cervical tissues from DES induced CIN, note Low intense 
of nuclear immunoepxression of Chk2 in cancer animals.  
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4.14 Effect of ZER on the expression of Bcl-2 gene of CIN induced 
female Balb/c mice. RTPCR products were analyzed using 2% 
agarose gel.  
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4.15 Effect of ZER on the expression of Bax gene of CIN induced 
female Balb/c mice. RTPCR products were analyzed using 2% 
agarose gel. 
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4.16 Effect of ZER on the expression of c-myc (218bp) gene of 
CIN induced female Balb/c mice. RTPCR products were 
analyzed using 2% agarose gel.  
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4.17.1 Liver of control mice (received 5% (v/v) ethanol + distilled 
water), showing normal histology in the centrilobular region of 
liver parenchyma. Magnification: 200X. 
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4.17.2 Liver of mice treated with a single dose of 20mg ZER /kg after 
24 hours showing normal histology in the parenchyma. 
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4.17.3 Liver of mice treated with a single dose of 100mg ZER /kg 
after 24 hours showing normal histology in the parenchyma. 
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4.17.4 Liver of mice treated with a single dose of 250mg ZER /kg 
after 24 hours showing normal histology in the parenchyma. 
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4.17.5 Liver of mice treated with ethanol 5% (v/v) showing focal 
inflammation in liver parenchyma. 
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4.17.6 Liver of mice treated with 20mg ZER /kg daily until day 14. 
Liver shows few hepatocytes undergoing degenerative changes 
and focal inflammation in liver parenchyma. 
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4.17.7 Liver of mice treated with 100mg ZER /kg daily until day 14. 
Liver shows few hepatocytes undergoing degenerative changes 
(arrows) in the periportal area.  
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4.17.8 Liver of mice treated with 250mg ZER/kg daily until day 14. 
Liver shows few hepatocytes undergoing degenerative changes 
(arrows) in liver parenchyma. 
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4.18 Effect of sub-chronic intraperitoneal administration of ZER 
(90 days) on the body weight of normal female Balb/c mice.  
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4.19 Serum concentration of AST in female Balb/c mice of 
different treatment groups (Control, 10 & 100 mg/kg).  
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4.20 Serum concentration of ALP in female Balb/c mice of 
different treatment groups (Control, 10 & 100 mg/kg).  
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4.21 Serum concentration of ALT in female Balb/c mice of 
different treatment groups (Control, 10 & 100 mg/kg).  
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4.22 Serum concentration of GGT in female Balb/c mice of 
different treatment groups (Control, 10 & 100 mg/kg).  
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4.23 Liver of female Balb/c mice treated with 5% v/v 
(EtOH/Distilled water) showing normal architecture. The 
hepatocytes (H) are radiating normally outward the central 
vein (C) and no abnormal histopathological lesions (score 0) 
were observed in this group. 
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4.24 Liver of female Balb/c mice liver treated with 10 mg ZER /kg. 
The hepatocytes reserve the healthy feature with few normal 
binuclear cells.   
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4.25 Liver of female Balb/c mice liver treated with 100 mg ZER 
/kg. The hepatocytes reserve the normal architecture. 
Hepatocellular arrays remain regular with mild intraradial 
congestion. 
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4.26 Kideny of female Balb/c mice kidney treated with 5% v/v 
(EtOH/Distilled water) showing the normal architecture. Renal 
tissue reveals no pathological lesions with healthy tubules and 
intact basement membrane 
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4.27 Kidney of female Balb/c mice kidney treated with 10mg/kg 
ZER shows normal architecture.  
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4.28 : Kidney of female Balb/c mice kidney treated with 100mg/kg 
ZER shows normal architecture. Note the tubule is normal 
with intact basement membrane, and a mild hyperemia is 
observed. 
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4.29 (a) Myocardial tissue of a control mouse showing normal 
architecture. (b) Heart of a mouse treated sub-chronically with 
10mgZER/kg showing normal myocyte. (c) Heart of a mouse 
treated sub-chronically with 100mgZER/kg showing normal 
architecture and normal coronary vessels.  
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6.1 Proposed scheme foe the mode of action of ZER. 221 
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0.05 Level of Significance (Type 1 error) 
106 1000,000 
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ACUC Animal Care and Use Committee  
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ALT Alanine Aminotransferase 
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B.W. Body weight  
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